首页> Journal for immunotherapy of cancer> Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype.

Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jasmin,Hatami

第一单位： Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria.

作者： Jasmin,Hatami ^[1] ; Krishna,Das ^[2] ; Leonie,Wolf ^[1] ; Andreas,Aufschnaiter ^[3] ; Janine,Kimpel ^[1] ; Tobias,Nolden ^[2] ; Liesa-Marie,Schreiber ^[4] ; Brigitte,Müllauer ^[1] ; Elke,Podgorschek ^[2] ; Theresa,Schwaiger ^[2] ; Bart,Spiesschaert ^[2] ; Guido,Wollmann ^[3] ; Knut,Elbers ^[2] ; Dorothee,von Laer ^[1] ; Zoltán,Bánki ^[5]

作者单位： Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria. ^[1] ViraTherapeutics GmbH, Rum, Tyrol, Austria. ^[2] Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria.;Department of Internal Medicine V, Tyrolean Cancer Research Center, Medical University of Innsbruck, Innsbruck, Tyrol, Austria. ^[3] Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria. ^[4] Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria zoltan.banki@i-med.ac.at. ^[5]

关键词 Adaptive Combination therapy Immune modulatory Oncolytic virus T-Lymphocytes